(CRBG) Corebridge Financial - Ratings and Ratios
Annuities, Life Insurance, Retirement Plans, Institutional Products
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 3.14% |
| Yield on Cost 5y | 5.85% |
| Yield CAGR 5y | 41.42% |
| Payout Consistency | 71.0% |
| Payout Ratio | 65.8% |
| Risk via 5d forecast | |
|---|---|
| Volatility | 29.4% |
| Value at Risk 5%th | 47.7% |
| Relative Tail Risk | -1.45% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.20 |
| Alpha | -16.43 |
| CAGR/Max DD | 0.72 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.417 |
| Beta | 1.368 |
| Beta Downside | 1.809 |
| Drawdowns 3y | |
|---|---|
| Max DD | 32.88% |
| Mean DD | 8.58% |
| Median DD | 7.22% |
Description: CRBG Corebridge Financial December 19, 2025
Corebridge Financial, Inc. (NYSE: CRBG) delivers retirement and insurance solutions across four business lines: Individual Retirement (fixed, indexed, and variable annuities), Group Retirement (in-plan recordkeeping, flexible annuities, and advisory services), Life Insurance (term, whole, index universal, and guaranteed universal life), and Institutional Markets (stable-value wraps, pension-risk-transfer annuities, private-placement life and annuity products, and guaranteed investment contracts). The firm, originally SAFG Retirement Services, was founded in 1998 and is headquartered in Houston, Texas.
Key recent metrics: Q3 2024 reported a 7% YoY increase in annuity premium volume, driven by rising interest-rate spreads that make fixed-index products more attractive; the Life Insurance segment posted a combined ratio of 92.3%, indicating underwriting profitability despite a competitive market. Macro-level drivers include the aging U.S. population-projected to push the 65-plus cohort to 22% of the population by 2030-and the Fed’s policy cycle, which influences the pricing of fixed-income-linked annuities and stable-value wraps.
For a deeper dive into CRBG’s valuation nuances, consider exploring ValueRay’s analytical tools.
Piotroski VR‑10 (Strict, 0-10) 3.5
| Net Income (991.0m TTM) > 0 and > 6% of Revenue (6% = 172.5m TTM) |
| FCFTA 0.00 (>2.0%) and ΔFCFTA -0.16pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 1939 % (prev 2579 %; Δ -640.7pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.00 (>3.0%) and CFO 1.62b > Net Income 991.0m (YES >=105%, WARN >=100%) |
| Net Debt (10.70b) to EBITDA (2.42b) ratio: 4.42 <= 3.0 (WARN <= 3.5) |
| Current Ratio 6.96 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (540.6m) change vs 12m ago -7.92% (target <= -2.0% for YES) |
| Gross Margin 80.35% (prev 78.73%; Δ 1.62pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 0.71% (prev 0.64%; Δ 0.06pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 3.50 (EBITDA TTM 2.42b / Interest Expense TTM 565.0m) >= 6 (WARN >= 3) |
Altman Z'' 1.08
| (A) 0.14 = (Total Current Assets 65.09b - Total Current Liabilities 9.36b) / Total Assets 411.29b |
| (B) 0.04 = Retained Earnings (Balance) 17.68b / Total Assets 411.29b |
| (C) 0.00 = EBIT TTM 1.98b / Avg Total Assets 405.36b |
| (D) 0.02 = Book Value of Equity 8.66b / Total Liabilities 396.97b |
| Total Rating: 1.08 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 42.64
| 1. Piotroski 3.50pt |
| 2. FCF Yield -4.27% |
| 3. FCF Margin 56.31% |
| 4. Debt/Equity 0.81 |
| 5. Debt/Ebitda 4.42 |
| 6. ROIC - WACC (= -5.88)% |
| 7. RoE 8.04% |
| 8. Rev. Trend -21.89% |
| 9. EPS Trend -51.60% |
What is the price of CRBG shares?
Over the past week, the price has changed by -0.42%, over one month by +2.63%, over three months by -7.00% and over the past year by +4.24%.
Is CRBG a buy, sell or hold?
- Strong Buy: 6
- Buy: 5
- Hold: 2
- Sell: 0
- Strong Sell: 1
What are the forecasts/targets for the CRBG price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 38.9 | 27.2% |
| Analysts Target Price | 38.9 | 27.2% |
| ValueRay Target Price | 33.7 | 10.1% |
CRBG Fundamental Data Overview December 24, 2025
P/E Trailing = 20.9456
P/E Forward = 5.8858
P/S = 0.847
P/B = 1.1468
Beta = 0.941
Revenue TTM = 2.88b USD
EBIT TTM = 1.98b USD
EBITDA TTM = 2.42b USD
Long Term Debt = 11.02b USD (from longTermDebt, last quarter)
Short Term Debt = 9.36b USD (from shortTermDebt, last quarter)
Debt = 11.02b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 10.70b USD (from netDebt column, last quarter)
Enterprise Value = -37.92b USD (15.53b + Debt 11.02b - CCE 64.47b)
Interest Coverage Ratio = 3.50 (Ebit TTM 1.98b / Interest Expense TTM 565.0m)
FCF Yield = -4.27% (FCF TTM 1.62b / Enterprise Value -37.92b)
FCF Margin = 56.31% (FCF TTM 1.62b / Revenue TTM 2.88b)
Net Margin = 34.47% (Net Income TTM 991.0m / Revenue TTM 2.88b)
Gross Margin = 80.35% ((Revenue TTM 2.88b - Cost of Revenue TTM 565.0m) / Revenue TTM)
Gross Margin QoQ = 81.35% (prev 81.41%)
Tobins Q-Ratio = -0.09 (set to none) (Enterprise Value -37.92b / Total Assets 411.29b)
Interest Expense / Debt = 1.23% (Interest Expense 135.0m / Debt 11.02b)
Taxrate = 426.2% (out of range, set to none) (-179.0m / -42.0m)
NOPAT = unknown (EBIT/Op.Income or Taxrate missing)
Current Ratio = 6.96 (Total Current Assets 65.09b / Total Current Liabilities 9.36b)
Debt / Equity = 0.81 (Debt 11.02b / totalStockholderEquity, last quarter 13.54b)
Debt / EBITDA = 4.42 (Net Debt 10.70b / EBITDA 2.42b)
Debt / FCF = 6.61 (Net Debt 10.70b / FCF TTM 1.62b)
Total Stockholder Equity = 12.32b (last 4 quarters mean from totalStockholderEquity)
RoA = 0.24% (Net Income 991.0m / Total Assets 411.29b)
RoE = 8.04% (Net Income TTM 991.0m / Total Stockholder Equity 12.32b)
RoCE = 8.48% (EBIT 1.98b / Capital Employed (Equity 12.32b + L.T.Debt 11.02b))
RoIC = 0.59% (EBIT 1.98b / (Assets 411.29b - Curr.Liab 9.36b - Cash 64.47b))
WACC = 6.47% (E(15.53b)/V(26.55b) * Re(11.06%) + (debt cost/tax rate unavailable))
Discount Rate = 11.06% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -7.59%
[DCF Debug] Terminal Value 69.62% ; FCFE base≈1.85b ; Y1≈2.02b ; Y5≈2.53b
Fair Price DCF = 54.60 (DCF Value 27.54b / Shares Outstanding 504.4m; 5y FCF grow 10.00% → 3.0% )
EPS Correlation: -51.60 | EPS CAGR: -42.85% | SUE: -0.93 | # QB: 0
Revenue Correlation: -21.89 | Revenue CAGR: -45.28% | SUE: -0.68 | # QB: 0
EPS next Quarter (2026-03-31): EPS=1.21 | Chg30d=+0.004 | Revisions Net=-7 | Analysts=11
EPS next Year (2026-12-31): EPS=5.35 | Chg30d=-0.028 | Revisions Net=-6 | Growth EPS=+22.5% | Growth Revenue=+9.8%
Additional Sources for CRBG Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle